Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652006 | 1.00 | ALOX15 (0.39) | ALOX15LMNAHSD17B10PARP10ALDH1A1 | |
| SCHEMBL7262827 | 0.78 | — | — | |
| SCHEMBL249765 | 0.78 | ADORA3 (0.37) | LMNAHSD17B10ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL17652003 | 0.78 | — | — | |
| SCHEMBL7351412 | 0.78 | ADORA3 (0.37) | LMNAHSD17B10ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL29030817 | 0.76 | LPAR3 (0.41) | LMNAALDH1A1 | |
| SCHEMBL23092079 | 0.75 | ALOX15 (0.42) | ALOX15LMNAHSD17B10PARP10ALDH1A1 | |
| SCHEMBL16028759 | 0.75 | — | — | |
| SCHEMBL10586858 | 0.74 | CYP4F2 (0.46) | ALOX15LMNAHSD17B10ALDH1A1CYP4F2 | |
| SCHEMBL2172424 | 0.74 | GAA (0.52) | ALOX15LMNAHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | claimed |
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2011-08-04 | — | — | US | claimed |
| CN-101784186-A | Improvements relating to organic compounds | SYNGENTA LTD | 2010-07-21 | — | — | CN | claimed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | claimed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | claimed |
| EP-3942934-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3201172-A1 | METHOD FOR THE MANUFACTURE OF N, N-DIALKYLLACTAMIDE | PURAC Biochem BV (NL) | 2017-08-09 | — | — | EP | disclosed |
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2016050894-A1 | METHOD FOR THE MANUFACTURE OF N, N-DIALLKYLLACTAMIDE | PURAC BIOCHEM BV (NL) | 2016-04-07 | — | — | WO | disclosed |
| CN-101784186-B | Improvements relating to organic compounds | SYNGENTA LTD. (GB) | 2014-10-08 | — | — | CN | disclosed |
| CN-101784186-B | Improvements relating to organic compounds | SYNGENTA LTD. (GB) | 2014-10-08 | — | — | CN | disclosed |
| CN-102209706-B | Process for producing N, N-dialkyl lactamide | PURAC BIOCHEM BV | 2014-07-23 | — | — | CN | disclosed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010037776-A1 | PROCESS FOR MANUFACTURING N,N-DIALKYL LACTAMIDE | PURAC BIOCHEM BV (NL) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009027624-A3 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| EP-0118743-B1 | CURABLE COMPOSITIONS CONTAINING URETHANES,AND THE USE OF THE COMPOSITIONS IN ELECTRODEPOSITION | PPG INDUSTRIES, INC. (US) | 1987-06-16 | — | — | EP | disclosed |
| US-4452930-A | FOR LOW TEMPERATURE CURING OF CATIONIC POLYMERS | PPG INDUSTRIES, INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4452963-A | CATIONIC POLYMER COATING COMPOSITIONS | PPG INDUSTRIES, INC. (US) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NR4A2, NR2C2, CYP4A22 | ALOX15 1734/4885LMNA 2395/4885HSD17B10 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.